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Available online 14 May 2016Increased aerobic glycolysis is a recognized feature ofmultiple cellular phenotypes and offers a potential point for
drug interference, as pursued by anti-tumor agents targeting theWarburg effect. This study aimed at examining
the role of aerobic glycolysis for migration of vascular smooth muscle cells (VSMC) and its susceptibility to the
small molecule indirubin-3′-monoxime (I3MO). Activation of VSMC with platelet-derived growth factor
(PDGF) resulted in migration and increased glycolytic activity which was accompanied by an increased glucose
uptake and hexokinase (HK) 2 expression. Inhibition of glycolysis or hexokinase by pharmacological agents or
siRNA-mediated knockdown signiﬁcantly reduced the migratory behavior in VSMC without affecting cell viabil-
ity or early actin cytoskeleton rearrangement. I3MO, previously recognized as inhibitor of VSMC migration, was
able to counteract the PDGF-activated increase in glycolysis and HK2 abundance. Activation of signal transducer
and activator of transcription (STAT) 3 could be identiﬁed as crucial event in upregulation of HK2 and glycolytic
activity in PDGF-stimulated VSMC and as point of interference for I3MO. I3MO did not inhibit hypoxia-inducible
factor (HIF)1α-dependent transcription nor inﬂuencemiRNA 143 levels, other potential regulators of HK2 levels.
Overall, we demonstrate that increased aerobic glycolysis is an important factor for the motility of activated
VSMC and that the anti-migratory property of I3MO may partly depend on impairment of glycolysis via a com-
promised STAT3/HK2 signaling axis.







Metabolic reprogramming, i.e. altered activity of selected energy
production or biosynthetic pathways, has emerged as crucial player in de-
termining the phenotype and signal transduction processes in a cell [1].
Already decades ago OttoWarburg noticed an increased rate of glycolysis
in tumor cells despite the presence of oxygen [2]. This so-calledWarburg
effect, previously thought to bemainly causedby impaired respiration but
now revised asmetabolic program required to fulﬁll the needs of a prolif-
erating tumor cell, has meanwhile consolidated as a hallmark of cancer
and potential target for anticancer therapy [3,4]. Although still studied
mainly in tumor models, a Warburg-like increased glycolytic rate also
appears to be inherent to non-malignant cells such as activated2243; DOG, deoxyglucose; ERK,
le factor; HK, hexokinase; HO,
orseradish peroxidase; I3MO,
lactate oxidase; Man, mannitol;
; Nrf2, nuclear factor E2 related
osphofructokinase; SI, STAT3
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. This is an open access article undermacrophages or lymphocytes or regenerating skeletal muscle cells
[5–7]. Moreover, in the vasculature inhibition of the glycolytic protein
phosphofructokinase 2 (PFK2/PFKB3) in endothelial cells was sufﬁcient
to counteract their migration [8]. The role of bioenergetics in migration
of vascular smoothmuscle cells (VSMC), the cell type surrounding the en-
dothelial monolayer in the vessel architecture, is little investigated. VSMC
migration is prominently involved in important (patho)physiological
processes such aswound healing, neoangiogenesis or vessel lumen con-
striction in the course of atherosclerosis or restenosis [9]. A bioenergetic
facet would render VSMCmigration an important (off) target to consid-
er in the design of potential drugs affecting cellular energy metabolism.
Indirubin-3′-monoxime (I3MO) is a derivative of indirubin which is
the active ingredient of the anti-leukemic traditional Chinese recipe
Dangghui Longgui Wan and shows improved pharmacokinetics com-
pared to its parent compound. Previouswork fromour group has extend-
ed the pharmacological research on I3MO fromcancer to vascular biology
and characterized I3MO as agent with triple vasoprotective bioactivity: it
impairs VSMC proliferation andmigration and counteracts inﬂammation
by direct inhibition of monocyte 5-lipoxygenase [10–12]. Based on
available data I3MO seems to also affect cellular energy metabolism by
inhibition of glycogen synthase kinase (GSK) 3 beta [13], a key enzyme
in glycogen metabolism, or by modulating mitochondrial function [14,
15]. Its role on VSMC bioenergetics has not been investigated until now.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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adopt a glycolytic phenotype, (ii) to what extent inhibition of glycolysis
affects the motogenic activity of VSMC and (iii) whether the previously
observed anti-migratory property of I3MO can be connected with
changed bioenergetics.
2. Materials and methods
2.1. Materials and reagents
I3MO was purchased from Enzo Life Sciences (Lausen, Switzerland),
the HIF 1α inhibitor BAY 87–2243 was from Selleck (via THP Medical
Products, Vienna/Austria) and the STAT3 inhibitor SI 602 was ordered
from Santa Cruz (Heidelberg, Germany). PDGF-BB was from Bachem
(Weil am Rhein, Germany). Other chemicals unless stated otherwise
were obtained from Sigma-Aldrich (Vienna, Austria). The anti-actin-anti-
bodywas obtained fromMP Biomedicals (Solon, OH, USA), the anti-PFK1
and anti-HK1 antibodies were ordered from Novus Biologicals (via THP
Medical Products) and all other primary as well secondary antibodies
were purchased from New England Biolabs (Heidelberg, Germany). All
sterile cell culture material was from Greiner (Frickenhausen, Germany).
2.2. Cell culture
Primary rat aortic VSMC were purchased from Lonza (Braine-
L'Alleud, Belgium). For experiments, they were thawed, cultivated in
Dulbecco's modiﬁed essential medium (DMEM)–F12 (1:1) supple-
mented with 20% serum, 30 μg/mL gentamicin, and 15 ng/mL
amphotericin B (Braine-L'Alleud, Belgium) and used between passage
4 and 15. Chinese hamster ovary cells (CHO-K1) were obtained from
ATCC and also cultivated in DMEM supplemented with 10% FCS.
2.3. Wound healing assay (scratch assay)
The scratch assay was performed as previously described in [11].
2.4. Boyden chamber assay (transwell assay)
Serum- starved VSMC (0% serum, 24 h) were seeded at a density of
200,000 cells/well into pre-collagen I coated (5 μg/cm2 rat collagen I; BD
Biosciences, SanDiego, CA, USA) cell culture inserts (BD Biosciences, San
Diego, CA, USA). Chemotaxis was initiated by addition of 10 ng/ml PDGF
(10.5 h)to the lower chamber. Cells were then stained with 8 μM
Calcein- AM (Merck Millipore, Billerica, MA, USA) for 20 min. Cells on
the upper side of the inserts (non-migrated cells) were completely
scraped off with a Q-tip and washed away with PBS. Cells on the
lower side of the inserts (migrated cells) were visualized under the mi-
croscope (Olympus Corporation, Tokyo, Japan) and photographed.
2.5. Determination of extracellular acidiﬁcation and respiratory rates by ex-
tracellular ﬂux analysis
VSMC were seeded in appropriate collagen-coated 24-well cell cul-
ture plates (from Seahorse Biosciences, Copenhagen, Denmark) at a
cell density of 2 × 104 cells/well and treated as indicated. Cells were
then kept in serum and glucose free assay medium (DMEM; pH 7.35–
7.40) at 37 °C and ambient CO2 for one hour before they were subjected
to assessment of the extracellular acidiﬁcation (ECAR inmpH/min) [and
oxygen consumption rate (OCR in pmolO2/min) if needed]. Appropriate
test kits came from Seahorse Biosciences, were performed according to
the manufacturer's instructions and analyzed on a Seahorse 24XFe ex-
tracellular ﬂux analyzer and Wave software (www.seahorsebio.com)
as described previously in [16,17]. Optimized inhibitor concentrations
for VSMC were 3 μM oligomycin and 100 mM 2-deoxyglucose (2-
DOG). Normalization to cell mass was routinely performed by crystal
violet staining after the analysis in order to account for potentialdifferences in cell number. Basal glycolytic activities were taken as read-
out and were calculated as follows: ECAR upon injection of glucose
corrected for non-glycolytic acidiﬁcation (ECAR in the presence of DOG).
2.6. Determination of extracellular lactate levels
VSMC were seeded in 24-well plates and treated as indicated. Then
cells were incubated with Krebs Ringer HEPES Glucose (KRHG) buffer
(50 mM HEPES, 136 mM NaCl, 23.5 mM KCl, 1.25 mM MgSO4,
1.25 mM CaCl2, 10 mM glucose and 0.1% BSA) for 1 h. Then an aliquot
of the supernatant was mixed 1:1 with an AmplexRed/lactate oxidase
(LO) solution (20 μMAmplex Red (Invitrogen), 0.5 mU/mL horseradish
peroxidase (HRP), 0.1 U/mL LO in KRHG buffer) in order to monitor lac-
tate levels. Lactate in the supernatant is oxidized by LO under stoichio-
metric production of H2O2 which in turn is used by HRP to oxidize
Amplex Red to the ﬂuorescent resoruﬁn whose ﬂuorescence is then
read at ex 535 nm/em590 nm in a TECANGenios Pro ﬂuorescence read-
er (TECANGroup Ltd., Männedorf, Switzerland)within the ﬁrst 5min of
the reaction. Like this lactate levels can be quantiﬁed based on a stan-
dard curve with solutions of known lactate concentrations and referred
to the protein concentration of the producing cells.
2.7. Determination of the cellular glucose uptake rate
The cellular glucose uptake rate was performed as previously de-
scribed elsewhere [17].
2.8. Analysis of cell integrity
VSMC were treated as indicated before they were subjected to a
trypan blue exclusion assay using an automated Vicell analyzer
(Beckman Coulter) in order to assess cell integrity and viability.
2.9. siRNA-mediated knockdown of HK2, Nrf2 or STAT3
VSMC were seeded in appropriate dishes and grown to 60%
conﬂuency. Then cells were washed with Opti-MEM® (Gibco™,
ThermoFisher Scientiﬁc, Vienna, Austria) and transfected with 60 to
200 nM siRNA- targeting rat HK-2, Nrf2 or STAT3 (Silencer Select
predesigned fromAmbion, Life Technologies, Vienna, Austria) or scram-
bled- siRNA (Ambion, Life Technologies, Vienna, Austria) using
oligofectamine according to the manufacturer's instructions
(Invitrogen, ThermoFisher Scientiﬁc, Vienna, Austria). After 5 h cells
were given fresh medium and then used and prepared (i.e. reseeded
and starved) for the planned assays.
2.10. Immunoblot
Extraction of proteins, electrophoresis, transfer, immunodetection
and densitometric evaluation were performed as previously described
[11].
2.11. F-actin staining by phalloidin-FITC
Coverslips were coated with 350 μg/ml rat collagen I solution in
0.02 N acetic acid (BD Bioscience Pharmingen, San Diego, CA, USA) for
2 h at room temperature. Coverslips were carefully washed twice with
PBS, dried under sterile conditions and stored for up to 3 days at 4 °C.
Cells were seeded at a density of 2 × 105 cells/well on to collagen I coat-
ed coverslips in 12-well plates for 24 h. Cells were then serum-starved
for 48 h, pretreated with mannitol or DOG for 30min and subsequently
stimulated with PDGF-BB (10 ng/ml) for 1 h. Samples were brieﬂy
rinsed with PBS and extracted with a prewarmed solution of 0.25% Tri-
ton X-100, 50% glutaraldehyde in a buffer containing 150 mM NaCl,
5 mM EGTA, 5 mM MgCl2, 5 mM Glucose, 10 mM MES (2-(N-
Morpholino)-ethansulfonic acid), pH 6.1 for 1 min. Cells were postﬁxed
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15 min, rinsed and washed with PBS for a few minutes. Coverslips
were incubated with FITC-labeled phalloidin solution (New England
Biolabs) for 30 min in a dark and humiﬁed chamber at room tempera-
ture. The coverslips were washed three times with PBS for 5 min and
mounted on a glass slide using ProLong Gold antifade mounting medi-
um (New England Biolabs, Heidelberg, Germany). After drying over-
night in the dark the specimens were analyzed using a confocal
ﬂuorescence microscope (Leica Microsystems, Wetzlar, Germany).Fig. 1. PDGF-triggered VSMCmigration is accompanied by an increase in glycolytic activity, glu
wound healing (scratch) assay with or without stimulation with 10 ng/ml PDGF-BB for 21 h Gr
mean + SD.; * p b 0.05; Student's t-test). (B) Quiescent VSMC were subjected to a Boyden Cha
were visualized by calcein-AM staining and photographed. Representative pictures of three ind
quiescent and PDGF-stimulated (6 h) VSMC was determined by extracellular ﬂux analysis as d
mean + SD.; * p b 0.05; Student's t-test) (D) Extracellular lactate accumulation was determin
subsequent correction for protein concentration. Bar graph depicts compiled data of three i
glucose uptake rate in quiescent and PDGF-stimulated (10 ng/mL; 6 h) VSMC was determi
experiments (n = 3, mean + SD.; * p b 0.05; Student's t-test) (F) Quiescent VSMC were stim
were subjected to western blot analyses for HK2, actin, HK1, PFK1 and 2. Bar graph depict
mean + SD.; * p b 0.05; ANOVA, Dunnett vs unstimulated control).2.12. Small G- protein pulldown assay
VSMC were seeded in 10 cm dishes and grown to 80% conﬂuence.
After 48 h of serum starvation cells were treated and stimulated as indi-
cated, washed twice with ice-cold PBS and subsequently lysed. 20 μL of
the lysate was taken away as input control. The remaining volume was
subjected to a pulldown of activated rac and cdc42 using PAK-PBD se-
pharose beads (BioVision) and analyzed by an immunoblot for rac and
cdc42, respectively.cose uptake and hexokinase 2 expression. (A) Serum-deprived VSMCs were subjected to a
aphs indicate relative values of wound closure as assessed by CellProﬁler Software (n=3,
mber chemotaxis assay using 10 ng/mL PDGF (6 h) as chemotactic stimuli. Migrated cells
ependent biological replicates with consistent results are shown. (C) Glycolytic activity in
escribed. The bar graph depicts compiled data of three independent experiments (n= 3,
ed after PDGF stimulation (10 ng/mL, 6 h) by an enzyme-based ﬂuorescence assay and
ndependent experiments (n = 3, mean + SD.; * p b 0.05; Student's t-test) (E) Cellular
ned in an isotope-based assay. Bar graph depicts compiled data of three independent
ulated with PDGF (10 ng/mL) for the indicated periods of time before total cell extracts
s compiled densitometric data (HK2/actin) of three independent experiments (n = 3,
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CHO cells were grown in 10 cm dishes to 70% conﬂuency and tran-
siently transfected with a HIF1α-dependent luciferase reporter construct
(pGI3-EPO-HRE, [18]; kind gift fromThomasKietzmann) and an EGFP ex-
pression plasmid (from ClonTech) using Lipofectamine Plus reagent ac-
cording to the manufacturer's instructions. 16 h after transfection and
recovery cells were harvested and re-seeded in 96-well plates
(5 × 104 cells/well) and serum starved till the next day. Then cells were
treated as indicated for 8 h before the luminescence of the ﬁreﬂy lucifer-
ase and the ﬂuorescence of EGFP were quantiﬁed on a GeniosPro plate
reader (TECAN Group Ltd., Männedorf, Switzerland). The luminescence
signals were normalized to the EGFP-derived ﬂuorescence in order to ac-
count for differences in cell number and/or transfection efﬁciency.Fig. 2. Inhibition of glycolysis overcomes PDGF-induced VSMCmigration. (A) Serum-deprived V
5mM) and lonidamine (LON10 and 25 μM) for 30min as indicated and subjected to awound h
indicate relative values of wound closure as assessed by CellProﬁler Software (n=3,mean+ S
(Man, ctrl), and deoxyglucose (DOG), 30mM; or 200 nM siRNA) subjected to a Boyden Chambe
visualized by calcein-AMstaining and photographed. Representative pictures of at least two inde
viability of VSMCwere determined upon treatmentwith deoxyglucose (DOG) or lonidamine (LO
3, mean + SD.; * p b 0.05; ANOVA, Dunnett vs untreated control).2.14. Analysis of miR 143 levels
For this, 0.2 × 106 VSMCs between passage 4 and 8were seeded into
each well of six-well plates, starved for 48 h, treated as indicated and ﬁ-
nally stimulated with PDGF-BB for up to 24 h. Total RNA, including
microRNAs, was isolated from cellular samples with TRIzol reagent
(Life Technologies Inc., Carlsbad, CA, USA) by applying a slightly modi-
ﬁed protocol. 1-bromo-3-chloropropane was used instead of chloro-
form for phase separation and samples received an additional wash
with 70% ethanol compared to themanufacturer's protocol. The isolated
RNAwas subjected to DNAse digestion (DNA-free kit, Life Technologies
Inc) to increase sample purity. The quality of the isolated RNA was de-
termined by UV-spectrophotometry (NanoDrop, Thermo Scientiﬁc,
Willmington, DE, USA) and agarose electrophoresis. ReverseSMCs were pretreatedwithmannitol (Man; 5 mM; osmotic control), deoxyglucose (DOG,
ealing (scratch) assaywith orwithout stimulationwith 10 ng/ml PDGF-BB for 21 h. Graphs
D.; * p b 0.05; Student's t-test). B) Quiescent VSMCwere pretreated as indicated (Mannitol
r chemotaxis assay using 10 ng/mL PDGF (6 h) as chemotactic stimuli. Migrated cells were
pendent biological replicateswith consistent results are shown. (C)Glycolytic rate and (D)
N) as indicated by extracellularﬂux analysis and trypan blue exclusion, respectively. (n=
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sample using themiScript II RT kit provided by QIAGEN (Hilden, Ger-
many). Relative quantiﬁcation of miR-143 levels via quantitative
real-time PCR (qPCR) was performed on a LightCycler 480 instru-
ment (Roche Diagnostics, Mannheim, Germany) using the miScript
SYBR green PCR kit and a miScript primer assay speciﬁc for miR-
143 (both QIAGEN). U6 snRNA was used as a reference gene (primer
assay from QIAGEN).2.15. Statistics
At least three independent biological replicates of each experiment
were performed. Error bars in the pictures represent the SD (standard
deviation) of the mean. Statistical signiﬁcance was determined by
using Student‘s t-test or by one-way or two-way ANOVA followed by
Bonferroni's or Dunnett's post test. All statistical analyses were done
with GraphPad Prism. P-values b0.05 were considered as signiﬁcant
and are designated with * in the respective ﬁgures.Fig. 3. Inhibition of glycolysis does not interfere with early actin cytoskeleton reorganiza
pretreatment with mannitol (Man, 30 mM, osmotic control) or deoxyglucose (DOG, 30
microscope. Stress ﬁbers, lamelli –and ﬁlopodia are indicated with the appropriate arro
(30 mM DOG) for 30 min as indicated before they were stimulated with PDGF (10 ng/m
An aliquot served as input control. Representative immunoblots from three independent
performed experiments. (n = 3, mean + SD.; *, # p b 0.05; ANOVA, Dunnett (vs respective
deoxyglucose (30 mM DOG) for 30 min as indicated before they were stimulated with PDG
indicated. Representative blots from three independent experiments are depicted.3. Results
3.1. PDGF triggers migration and increased glycolysis in primary rat aortic
VSMC
VSMC were stimulated with platelet derived growth factor (PDGF)
and served as model system to study the role of bioenergetics for
VSMC migration. As reported previously (e.g. [12,19,20]), PDGF treat-
ment of quiescent VSMC led to a signiﬁcant increase in their migratory
activity as seen in a scratch assay after 21 h (Fig. 1A). This period of
time is shorter than the duration of one cell division cycle under the
used cell culture conditions (i.e. 30± 1.5 h), excluding amarked contri-
bution of proliferation to wound closure. Accordingly, a control experi-
ment performed in the presence of the proliferation inhibitor
mitomycin showed comparable wound closure (Supplemental Fig. 1).
Moreover, PDGF triggered chemotaxis of VSMC in a Boyden chamber
transwell assay, corroborating the pro-migratory impact of PDGF in
VSMC(Fig. 1B). Using extracellularﬂux analysis and assessing the extra-
cellular acidiﬁcation rate (ECAR) showed an enhanced glycolytic rate intion. (A) Quiescent VSMC were stimulated with PDGF (10 ng/mL; 1 h) after 30 min
mM). Cells were ﬁxed, stained with FITC phalloidin and viewed under a confocal
ws. (B) Quiescent VSMC were treated with 30 mM mannitol (−) or deoxyglucose
L) for 3 min. Lysates were then subjected to pulldown of GTP bound ras and cdc42.
experiments ae depicted. The bar graph shows compiled densitometric data from all
unstimulated control). (C) Quiescent VSMC were treated with 30 mM mannitol (−) or
F (10 ng/mL) for 5 or 15 min. Lysates were then subjected to immunoblots analyses as
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lular lactate levels were monitored which excluded altered activity of
membrane-residing proton pumps as culprit for the observed extracel-
lular acidiﬁcation (Fig. 1D). The unambiguous increase in glycolytic ac-
tivity was accompanied by an enhanced cellular glucose uptake rate
by activated VSMC (Fig. 1E) and only a slight reduction in the oxygen
consumption rate (Supplemental Fig. 2). VSMC activation with PDGF
furthermore led to a time-dependent induction of hexokinase (HK) 2
with no marked effect on HK1-, PFK1-, or PFK2 abundance (Fig. 1F),
other rate controlling glycolytic enzymes. HKs catalyze the ﬁrst step in
glycolysis, i.e. phosphorylation of glucose to glucose-6-phosphat. HK oc-
curs in four isoforms with partly cell-type speciﬁc expression proﬁles
and HK2 being the principle regulated isoform, mainly expressed in
myocytes and heavily involved in metabolic reprogramming.
3.2. Inhibition of glycolysis interferes with migration of VSMC
Subsequent examination of the migratory potential of activated
VSMC when glycolysis was blunted intended to delineate a potential
connection between bioenergetics and motility. Treatment with
deoxyglucose (DOG), lonidamine- both glycolytic inhibitors [21,22]–,
and siRNA mediated knockdown of HK2 (knockdown efﬁciencyabout
60% on protein level) consistently resulted in reduced PDGF-induced
migration (Fig. 2A and B) suggesting that activated VSMC are indeed de-
pendent on glycolysis in order tomove. The used concentrations of DOG
(5 mM for long-term and 30 mM for short term incubations) andFig. 4. The antimigratory activity of I3MO is accompanied by a reduced glycolytic rate and dimin
to awound healing (scratch) assaywith orwithout stimulationwith 10 ng/ml PDGF-BB in the p
by CellProﬁler Software (n=3,mean+ SD.; * p b 0.05; Student's t-test). (B) Glycolytic activity
5 μM)was determined by extracellular ﬂux analysis as described. The bar graph depicts compile
(C) Serum-deprived VSMCwere pretreatedwith 5 μM I3MO and then stimulatedwith PDGF (10
Representative blots from three independent experiments and compiled densitometric analyslonidamine (10 and 25 μM) successfully interferedwith glycolytic activ-
ity (Fig. 2C) and did not cause any reduction in cell viability (Fig. 2D)
which could possibly have contributed to the reduced motility of the
cells. As glycolytic ATP was reported to be crucial for actin reorganiza-
tion in endothelial cells [8], we had a look whether glycolysis inhibition
also affects this crucial step for cell movement in VSMC. However, inhi-
bition of glycolysis with DOGdid not result in an obvious impairment of
actin cytoskeleton reorganization. PDGF induced the formation of stress
ﬁbers, lamellipodia and ﬁlopodia in both control and DOG (30 mM)-
treated cells as evident in themicroscopic pictures after F-actin staining
with FITC-phalloidin (Fig. 3A). This ﬁnding was conﬁrmed by the indis-
tinguishable activation of rac1 and cdc42, small G-proteins with a pivotal
role in lamellipodia and ﬁlopodia formation [23,24], respectively, in con-
trol and DOG-treated VSMC upon PDGF exposure (Fig. 3B). Initially per-
formed pilot experiments excluded an inﬂuence of DOG on basal rac or
cdc42 activation. Unfortunately, rho A which is mainly involved in stress
ﬁber formation could not successfully be immunoprecipitated from
VSMC (as already experienced in [25]). Phosphorylation and activation
of mitogen-activated protein (MAP) kinases, i.e. p38, ERK1/2 and JNK,
or AKT kinase which are further events during actin cytoskeleton reorga-
nization and migration (e.g. [26,27]) were not negatively affected by gly-
colysis inhibition, either (Fig. 3C). Therewas even a reproducible trend for
enhanced and/or prolonged phosphorylation for some of those kinases in
DOG-treated cells which could be explained by the redox sensitivity of
the kinases and increased ROS production after DOG exposure. So far
our ﬁndings showed that activated VSMC shift their energy metabolismished HK2 induction in PDGF-activated VSMC. (A) Serum-deprived VSMCswere subjected
resence of 2.5 and 5 μM I3MO. Graphs indicate relative values ofwound closure as assessed
in quiescent and PDGF-stimulated (6 h) VSMC in the absence or presence of I3MO (2.5 and
d data of three independent experiments (n=3,mean+ SD.; * p b 0.05; Student's t-test).
ng/mL) for 6 h. Total cell lysateswere subjected to immunoblot analysis for HK2 and actin.
is are depicted (n= 3, mean + SD.; * p b 0.05; ANOVA, Bonferroni).
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but apparently not for early actin reorganization.
3.3. The anti-migratory small molecule I3MO abrogates increased glycolysis
in activated VSMC
Intrigued by the revealed link between glycolysis and migration in
VSMCwe checked whether the antimigratory activity of the small mol-
ecule I3MO, recently uncovered in PDGF- or leukotriene-activated
VSMC ([12]+ Fig. 4A), may carry a bioenergetic facet. Extracellular
ﬂux analysis indeed revealed an abrogated increase in glycolysis in acti-
vated VSMC treatedwith I3MO at 2.5 and 5 μM(Fig. 4B), concentrations
that also negatively affectmigration (Fig. 4A). The diminished glycolytic
shift was in line with a reduction in PDGF-induced HK2 expression by
I3MO (Fig. 4C). These ﬁndings indicate that I3MO is able to successfullyFig. 5. STAT3 positively regulates HK2 expression in PDGF stimulated VSMC and its inhibition
200 nM siRNA (scr or targeting Nrf2), after 24 h recovery starved for 18 h and then either tre
inhibitor MG132 (10 μM) for 4 h (lower panel). Cells were lysed and total cell lysates subje
Representative blots and compiled densitometric data from three independent experiments
were pretreated with 50 and 100 μM of the STAT3 inhibitor SI-602 for 30 min and then expos
for HK2 and actin. Representative blots and compiled densitometric data are depicted. (n= 3
200 nM siRNA targeting STAT3 with a constant total siRNA concentration of 200 nM in all s
PDGF for 8 h. Cells were lysed and immunoblotted for STAT3, HK2 and actin. Representative
(D) Glycolytic activity in quiescent and PDGF-stimulated (6 h) VSMC in the presence and abs
as described. The bar graph depicts compiled data of three independent experiments (n = 3
transfected with 200 nM scrambled siRNA or siRNA targeted versus STAT3 were subjected to
Graphs indicate relative values of wound closure as assessed by CellProﬁler Software (n= 3, movercome the PDGF-induced rise in glycolytic activity and to inhibit in-
duction of HK2.
3.4. Impaired STAT3 signaling contribute to reduced HK2 expression and
glycolysis in I3MO-treated activated VSMC
I3MO is a small moleculewith pleiotropic actions and targets [28]. In
PDGF-stimulated VSMC, I3MO acts as activator of Nrf2 — and inhibitor
of STAT3 signaling by interferingwith Y705 phosphorylation [11,12], re-
spectively. We therefore examined the role of the two transcription fac-
tors for PDGF-induced HK2 expression and modulation by I3MO.
Comparing VSMC with siRNA-depleted Nrf2 (knockdown by approxi-
mately 85%) to control cells revealed no difference in I3MO's capability
of blunting PDGF-induced HK2 expression (Fig. 5A). Thus, the activation
of Nrf2 by I3MO apparently does not directly account for the observedis connected with decreased glycolysis and migration. (A) VSMC were transfected with
ated with I3MO (5 μM)/PDGF as indicated for 8 h (upper panel) or with the proteasome
cted to western blot analysis for Nrf2 or actin and hexokinase or tubulin, respectively.
are depicted. (n = 3, mean + SD.; * p b 0.05; ANOVA, Bonferroni). (B) Quiescent VSMC
ed to PDGF (10 ng/mL) for 6 h. Total cell lysates were subjected to immunoblot analysis
, mean + SD.; * p b 0.05; ANOVA, Bonferroni). (C) VSMC were transfected with 0, 60 or
amples (ﬁlled up with scrambled siRNA where needed), starved and then treated with
blots and compiled densitometric data of three independent experiments are depicted.
ence of the STAT3 inhibitor SI 602 (75 μM) was determined by extracellular ﬂux analysis
, mean + SD.; * p b 0.05; Student's t-test). (E) Serum-deprived VSMCs that were either
a wound healing (scratch) assay with or without stimulation with 10 ng/ml PDGF-BB.
ean + SD.; * p b 0.05; ANOVA, Bonferroni).
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hibitor SI-602 demonstrated that STAT3 is heavily involved in PDGF-in-
duced HK2 expression in VSMC (Fig. 5B). Consistent data were obtained
when employing Stattic, another STAT3 inhibitor (data not shown).We
aimed at corroborating this key ﬁnding for VSMC employing a siRNA-
mediated approach. Using a transient transfection protocol and two dif-
ferent concentrations of siRNA we could achieve knockdown efﬁcien-
cies of STAT3 between 45 and 70% which were reﬂected in a
diminished HK2 induction upon PDGF stimulation. This ﬁnding con-
ﬁrms the involvement of STAT3 in HK2 induction in VSMC (Fig. 5C) as
already previously shown for cancer cells [29,30]. In line with the re-
duced HK2 induction inhibition or depletion of STAT3 also diminished
the glycolytic rate andmigratory activity of PDGF-activated VSMC as ev-
ident by extracellular ﬂux analysis in the presence of SI-602 (Fig. 5D)
and reduced scratch closure by STAT3-depleted cells (Fig. 5E), respec-
tively. Induction of HK2 has also been linked with the activation of hyp-
oxia-inducible factor (HIF-1α) signaling, also a downstream effect of
activated STAT3, and with repression of microRNA 143 (e.g. [31–33]).
We therefore examined the potential inﬂuence of I3MO on those two
parameters. Also in PDGF-stimulated VSMCHK2 expressionwas report-
ed to be HIF1α-dependent [34]. Accordingly, the HIF inhibitor BAY 87-
2243 was able to signiﬁcantly suppress HK2 levels in our test system
(Fig. 6A). Reporter gene assays furthermore revealed that PDGF and co-
balt chloride, a chemical inducer of hypoxia, led to an increase of HIF1α-
dependent luciferase expression (Fig. 6B). However, I3MO activatedFig. 6. HIF1α-and miR143 signaling are not negatively inﬂuenced by I3MO. (A) Quiescent VSM
PDGF (10 ng/mL) for 6 h. Total cell lysates were subjected to immunoblot analysis for HK2 a
experiments are depicted (n = 3, mean + SD.; * p b 0.05; ANOVA, Bonferroni). (B) CHO c
construct and serum-deprived. Cells were treated as indicated with I3MO (3 and 5 μM), PDG
activity was assessed and corrected for EGFP ﬂuorescence. Bar graph depicts data from thr
Quiescent VSMC were treated with PDGF for the indicated periods of time before levels of mi
vs unstimulated control). (D) Quiescent VSMC were pretreated with DMSO or I3MO for 30 m
levels were determined as described. (n ≥ 6, mean + SD, n.s. p N 0.05).HIF-1α-dependent reporter gene expression both under basal and
PDGF- or cobalt-treated conditions (Fig. 6B) which disqualiﬁed HIF1α
inhibition as responsible factor for the reduced HK2 expression by
I3MO. Examination of miR 143 levels in VSMC disclosed an expected
transient and time-dependent decrease in miR 143 upon activation
with PDGF (Fig. 6C) which, however, was not signiﬁcantly altered by
I3MO (Fig. 6D). From these data we conclude that I3MO most likely in-
terfereswith STAT3- and not HIF-1α ormiR 143 signaling in order to re-
duce HK2 expression and glycolysis in activated VSMC. Of note and in
contrast to Y705, STAT3 phosphorylation at S727 which was found to
markedly modulate mitochondrial function [35] was not affected by
I3MO at 5 μM (Supplemental Fig. 3).
4. Discussion
Themain new ﬁndings of this study are that (i) the glycolytic pheno-
type adopted by VSMC upon PDGF stimulation is crucial to provide
themwith a full migratory potential and (ii) I3MO abrogates this meta-
bolic change and interferes with the STAT3-HK2 signaling axis.
Increased aerobic glycolysis appears as common cellular response to
different cues and needs and is not restricted to cancer cells. This study
showed that stimulation with the pro-migratory PDGF led to an elevat-
ed glycolytic rate in VSMC, in line with previous reports using PDGF as
mitogen [36–38]. The raised glycolytic rate turned out as essential pre-
requisite for VSMC motility and was accompanied by an increasedC were pretreated with 10 or 30 μMHIF inhibitor BAY 87–2243 and then stimulated with
nd actin. Representative blots and compiled densitometric data from three independent
ells were transiently transfected with a HRE-LUC reporter gene and EGFP expression
F (10 ng/mL) and CoCl2 (200 μM) or HIF 1α inhibitor (10 μM) for 8 h before luciferase
ee independent experiments. (n = 3, mean + SD.; * p b 0.05; ANOVA, Bonferroni) (C)
RNA 143 were determined as described (n= 5, mean + SD; * p b 0.05; ANOVA, Dunnett
in prior to PDGF stimulation for the indicated periods of time. Then relative miRNA 143
55E.H. Heiss et al. / Vascular Pharmacology 83 (2016) 47–56cellular glucose uptake and increased expression of HK2. HK2 is
assigned not only a crucial role for boosting glycolysis but also for cellu-
lar survival. Its direct interaction with VDAC (voltage dependent anion
channel), ANT (adenine nucleotide translocase) and cyclophilin D at
the outer mitochondrial membrane prevents mitochondrial membrane
transition pore opening and apoptosis [39,40]. It remains to be investi-
gated whether HK2 in PDGF-activated VSMC is bound to mitochondria
and also plays a role in cytoprotection. Inhibition of HK activity by
DOG and lonidamine and depletion of cells from HK2 by siRNA did not
markedly affect cell viability under our experimental conditions,
though.
Glycolytic inhibition by pharmacological or siRNA-mediated means
signiﬁcantly blunted migration which to our knowledge has not been
reported before for VSMC. In contrast to endothelial cells, in which
PFKB3 plays a major role in the metabolic control of motility, HK2 ap-
peared as the predominantly modulated glycolytic protein when
looking at abundance and thus remained focus of this study. However,
changes in enzyme activity of other glycolytic enzymes, e.g. via post-
translational modiﬁcation, cannot be excluded in our system. Inhibition
of glycolysis in activated VSMC did not obviously affect cytoskeletal
actin reorganization. PDGF- activated cells phenotypically showed for-
mation of stress ﬁbers, lamelli-and ﬁlopodia, and on the molecular
level activation of rac and cdc42 as well as phosphorylation of MAPK
and AKT took place regardless of the presence of DOG (or I3MO, data
not shown). Future studies need to pin down the step in the migratory
cascade from polarization over protrusion and attachment to contrac-
tionwhich is affected by the inhibition of glycolysis in VSMC. Special at-
tention should be given to changes in ATP levels (total or local at
protrusions) and also to the question whether potential changes in
the respiratory capacity contribute to VSMC motility.
I3MO, which we previously had identiﬁed as anti-migratory
agent in VSMC due to activation of the Nrf2/heme oxygenase (HO)-
1 axis, was for the ﬁrst time revealed to signiﬁcantly abrogate the
PDGF-triggered increase in glycolytic activity and HK2 expression.
Nrf2 knockout cells had been reported to show an elevated glycolytic
rate [41], in line with the tested hypothesis that Nrf2 activation by
I3MO accounted for reduced HK2 expression. However, knockdown
of Nrf2 in VSMC showed that I3MO inhibited PDGF-induced HK2 ex-
pression regardless of Nrf2 presence. We therefore excluded phar-
macological activation of Nrf2 by I3MO as major mechanism
responsible for the observed reduction in HK2 abundance. It ap-
peared that I3MOmay inhibit VSMC migration by at least two mech-
anisms, (i) induction of the Nrf2/HO-1 axis as shown in [12] and (ii)
an Nrf2-independent abrogation of HK2 induction. However, al-
though without direct inﬂuence on HK2 expression, an activated
Nrf2/HO-1 axis may still be involved in the dampened glycolytic ac-
tivity. An increased HO-1 signaling has recently been shown to lead
to diminished glycolysis in favor of the pentose phosphate pathway
via altered PFKB3 methylation [42]. Whether this applies in I3MO-
treated VSMC and could link together Nrf2 activation, reduced gly-
colysis and blunted migration warrants further investigation.
HK2 induction underlies a complex regulation including the control
via STAT3, HIF-1α, andmiR 143. Using selective STAT3 or HIF-1α inhib-
itors as well as siRNA-mediated depletion of STAT3 we could conﬁrm
that HK2 expression is dependent on both transcription factors in
PDGF-stimulated VSMC. However, whereas I3MOmarkedly suppressed
Y705 phosphorylation and activation of STAT3, it was not able to nega-
tively interfere with HIF-1α signaling or alter changes in miR 143 levels
in activated VSMC. In a HRE- dependent luciferase reporter gene assay,
I3MO rather enhanced than inhibited the HIF1α-dependent signal,
which is in linewith a previous report on indirubins [43]. However, tak-
ing into account that HIF-1α is also a STAT3 target gene [35,44] and
I3MOacts as an inhibitor of STAT3 signaling in VSMC [10,11] thisﬁnding
appears somewhat conﬂicting. But it needs to be noted that HIF1α sig-
naling is not solely inﬂuenced by STAT3-dependent de novo synthesis,
but also by other transcription factors triggering HIF1α expression, orby modulation of stability, posttranslational modiﬁcation or
transactivating potential of the protein [45] which could possibly pro-
vide a reconciling explanation.
5. Conclusion
Overall, we uncovered the importance of glycolysis for VSMCmigra-
tion and an anti-glycolytic facet in the activity proﬁle of I3MO via inhi-
bition of the STAT3/HK2 axis. The latter may not only inﬂuence
cellular motility but also contribute to the reported anti-proliferative
and anti-inﬂammatory actions of I3MO since also proliferation and in-
ﬂammation partly rely on an elevated glycolytic rate.
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